Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC

But Competition Intensifying

Executive Summary

Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.

You may also be interested in...



Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism

Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel